Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Global estimates indicated 2.3 million new cases of breast cancer in 2020, contributing to
nearly 12% of all new cancer cases, with 685 000 deaths in the same year. 1 Breast cancer …

Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …

PURPOSE To update recommendations on appropriate use of breast cancer biomarker
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-
SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer …

Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …